Servesto seeks to provide integrated drug discovery services to its partners with our state-of-the-art structural biology technology.
Dr. Padia has over 25 years of industrial experience in cutting edge drug discovery and development and has held management positions of increasing responsibility. Currently, Dr. Padia is working with University of Maryland (Center of Biomolecular Therapeutics) to evaluate and prioritize its project portfolio and to accelerate development of innovative drugs. He was Vice President, Drug R&D Services at Pharmaron and managed integrated projects for chemistry, lead optimization, preclinical candidate identification and development, and IND-enabling studies for clients. Prior to Pharmaron, Dr. Padia was Director of Chemistry and Drug Development at Avalon Pharmaceuticals where he oversaw a range of drug discovery and development programs and participated in the strategic management of the company. He has extensive experience in drug discovery and development processes, technology evaluation and implementation of project management tools to drive the projects to completion. He also has excellent knowledge drug development, formulation development, IND-enabling studies, GLP Tox evaluations, GMP drug manufacturing and regulatory affairs. Dr. Padia has also worked for ParkeDavis/Warner-Lambert (now Pfizer), Discovery Partners, and the NCGC-NCATS-NIH in the areas of Cancer, Cardiovascular and CNS therapeutics. Dr. Padia has led drug discovery and development efforts during his career that resulted in the identification of several development candidates in cancer and CNS area. Dr. Padia has authored several scientific publications and is also the inventor of many patents. Dr. Padia holds an adjunct position at the Georgetown University Medical Center and serves as an advisor for Drug Discovery Program at GUMC and NIDDK/NIH. He holds 14 patents or patent applications. He is serving as an editorial member of 2 journals and has authored more than 20 research articles.
Mr. Cary has been Chief Executive Officer of Cary Pharmaceuticals. Mr. Cary has pharmaceutical industry experience in research and development and business development. This experience has been gained at large and medium-sized pharmaceutical companies as well as at start-up ventures. Mr. Cary has participated in the identification, development, and commercialization of pharmaceutical products, has developed comprehensive product market plans and launched new products, established strategic alliances, and has performed due diligence for the acquisition of technologies and companies. From 1990 to 1994, Mr. Cary served as Vice President of Fuisz Technologies, Inc., a venture-capital-funded start-up company specializing in the development of broadly patented technologies with applications in the pharmaceutical, food, and confection industries. Mr. Cary has held numerous management positions at Abbott Laboratories, where he had responsibilities in new business development and research and development. While at Abbott, he was responsible for the development of AddVantage® and Patient-Controlled Analgesia®.
Mr. Farmer has over 25 years of experience leading the finance and accounting functions of development-stage life science companies. Most recently, he served as Vice President and Chief Financial Officer of Croma Pharmaceuticals North America, where he was responsible for managing all financial and operating activities of the US and Canadian operation. Prior to that position, Mr. Farmer served as Principal Accounting Officer for Avalon Pharmaceuticals, Inc. where he supported the company through it's Initial Public Offering and ultimate sale to Clinical Data, Inc. Mr. Farmer is a member of the American Institute of Certified Public Accountants (AICPA) and the Association of Biotech Financial Officers (ABFO).
Dr. Weber is a Professor of Biochemistry & Molecular Biology and the director of the Center for Biomolecular Therapeutics (CBT). The CBT is part of the University System of Maryland and has faculty from the University of Maryland-Baltimore (including the Schools of Medicine and Pharmacy) who manage state-of-the-art scientific, disciplinebased programs necessary for the discovery and regulation of disease targets including, but not limited to, genomics/bioinformatics, target identification and validation, assay development and high-throughput screening, protein production and characterization, structural biology, computer-aided drug design, medicinal chemistry, and in vivo testing and biology. We are also examining basic science questions pertaining to protein-protein interactions involving numerous other protein targets as possible therapeutic targets, so the significance of this work is very high. His lab also collaborates with principal investigators throughout the University System of Maryland on numerous structure, function, and drug design projects. He is serving as an editorial member of more than 10 journals, and has authored more than 150 research articles & book chapters involving basic science and biomedical therapeutics advances.